Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2019 Earnings Conference Call - Final Transcript
Feb 18, 2020 • 08:00 am ET
Greetings and welcome to the BrainStorm Cell Therapeutics Fourth Quarter 2019 Earnings Conference Call. [Operator Instructions] A question-and-answer session will follow the formal presentation. [Operator Instructions]
It is now my pleasure to introduce your host, Sean Leous with ICR. Please go ahead.
Thank you for joining the BrainStorm Cell Therapeutics fourth quarter and full year 2019 financial results conference. Before we begin the prepared remarks, we would like to remind listeners that this conference contains numerous statements, descriptions, forecasts, and projections regarding BrainStorm Cell Therapeutics, Inc. NASDAQ BCLI and its potential future business operations and performance, statements regarding the market potential for treatment of neurodegenerative disorders such as ALS and MS, the sufficiency of our existing capital resources for continuing operations in 2020 and beyond, the safety and clinical effectiveness of our NurOwn technology platform, our clinical trials of NurOwn and related clinical development programs, and our ability to develop strategic collaborations and partnerships to support our business planning efforts.
Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control, including the risks and uncertainties described from time-to-time in our SEC filings. Our results may differ material from those projected here on today's call. We undertake no obligation to publicly update any forward-looking statements.
Joining me today on the call will be Chaim Lebovits, President and CEO of BrainStorm; Dr. Ralph Kern, Chief Operating and Chief Medical Officer; and Preetam Shah, our Chief Financial Officer will be available to answer your questions during the Q&A session.
And now, it is my pleasure to introduce Mr. Chaim Lebovits, Chief Executive Officer of BrainStorm. Mr. Lebovits, you may begin.
Good morning. Let me begin by thanking everyone for joining today's call. 2019 was an exceptional year for BrainStorm. We continued to achieve milestone after milestone and we're holding this call to remind our shareholders of all that has been accomplished during this past exceptional year and what we expect for 2020. We remain fully committed to bringing much needed innovative cellular therapies to individuals with neurodegenerative diseases, to remain patient focused, and to advance our business objectives through scientific excellence.
Before I begin discussing 2019, I would like to first give you a more detailed update on our recent meeting with the FDA. This meeting was very important and was a watershed moment for our ALS development program. The Director of the Center for Biologics and Research, in short CBER proposed this meeting and senior leaders of CBER and all officials were present.
From our side, in addition to myself and Dr. Ralph Kern, we were accompanied by some of the principal investigators of our trial. We were also fortunate to have other world renowned leading ALS experts join us at this meeting. Brian Wallach, a person living with ALS and cofounder of I AM ALS attended and represented the patient voice because of being integral to every step of the development process for NurOwn.
Objectives of this meeting were to confirm that there is a clear